We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

39 hedge funds and large institutions have $14.9M invested in DiaMedica Therapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

32% more capital invested

Capital invested by funds: $11.2M → $14.9M (+$3.65M)

15% more funds holding

Funds holding: 34 → 39 (+5)

0.18% more ownership

Funds ownership: 14.93% → 15.11% (+0.18%)

54% less call options, than puts

Call options by funds: $138K | Put options by funds: $302K

Holders
39
Holders Change
+5
Holders Change %
+14.71%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
13
Reduced
7
Closed
3
Calls
$138K
Puts
$302K
Net Calls
-$164K
Net Calls Change
+$129K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$4.04M
2
AFM
Anson Funds Management
Texas
+$511K
3
CLG
Cooperman Leon G
+$393K
4
Two Sigma Investments
Two Sigma Investments
New York
+$261K
5
Citadel Advisors
Citadel Advisors
Florida
+$117K

Top Sellers

Rank Fund Capital Flow
1
MHP
Manatuck Hill Partners
Connecticut
-$504K
2
IC
Ikarian Capital
Texas
-$400K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$182K
4
BFM
Boothbay Fund Management
New York
-$40.4K
5
Simplex Trading
Simplex Trading
Illinois
-$39.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$4.46M +$4.04M +1,028,895 +621%
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.93M -$3.86K -984 -0.1%
CLG
3
Cooperman Leon G
$1.12M +$393K +100,000 +50%
JAMONY
4
Jacob Asset Management of New York
California
$1.03M – – –
IC
5
Ikarian Capital
Texas
$779K -$400K -101,959 -33%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$625K – – –
MHP
7
Manatuck Hill Partners
Connecticut
$540K -$504K -128,300 -47%
Two Sigma Investments
8
Two Sigma Investments
New York
$525K +$261K +66,577 +90%
AFM
9
Anson Funds Management
Texas
$485K +$511K +130,070 New
Two Sigma Advisers
10
Two Sigma Advisers
New York
$398K +$102K +26,000 +32%
Northern Trust
11
Northern Trust
Illinois
$378K +$61.7K +15,713 +18%
Citadel Advisors
12
Citadel Advisors
Florida
$245K +$117K +29,746 +83%
State Street
13
State Street
Massachusetts
$223K +$78.5K +20,000 +50%
BlackRock
14
BlackRock
New York
$219K +$10.2K +2,602 +5%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$186K – – –
Group One Trading
16
Group One Trading
Illinois
$126K +$37.9K +9,650 +40%
Morgan Stanley
17
Morgan Stanley
New York
$89K +$49.1K +12,500 +110%
Millennium Management
18
Millennium Management
New York
$83K +$87.4K +22,249 New
JF
19
Jump Financial
Illinois
$81K +$13.7K +3,500 +19%
BFM
20
Boothbay Fund Management
New York
$77K -$40.4K -10,301 -33%
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$52K -$182K -46,364 -77%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$44K +$46.7K +11,900 New
Marshall Wace
23
Marshall Wace
United Kingdom
$38K – – –
SC
24
Shay Capital
New York
$37K – – –
TRCT
25
Tower Research Capital (TRC)
New York
$35K +$31K +7,890 +537%
1
2

DMAC Hedge Fund Activity: Q4 2021 in Review

39 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2021, worth a combined $14.9M — up 32% from $11.2M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new DMAC positions and 3 closed out — a net gain of 5 holders — while 13 added to existing stakes and 7 trimmed.

The largest buyer was Stonepine Capital Management, adding an estimated $4.04M. The largest seller was Manatuck Hill Partners, cutting an estimated $504K.

  • 39 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2021, up from 34 in Q3 2021.
  • Funds reported $14.9M of DiaMedica Therapeutics stock for Q4 2021, up 32% quarter-over-quarter.
  • 8 funds opened new DiaMedica Therapeutics positions in Q4 2021 and 3 closed out, a net change of +5 holders.
  • The largest DiaMedica Therapeutics buyer in Q4 2021 was Stonepine Capital Management, an estimated $4.04M added.
  • The largest DiaMedica Therapeutics seller in Q4 2021 was Manatuck Hill Partners, an estimated $504K sold.

Based on aggregated 13F filings for Q4 2021.